Robert Michel
Until Robert L. Michel came along and founded The Dark Intelligence Group (DIG) two decades ago, the clinical laboratory industry and the anatomic pathology profession lacked a trustworthy source for information about the management and operations of medical laboratories. From its inception in 1995, The Dark Report quickly became the “go to” source of industry intelligence, innovations in lab management, and strategic market analysis.
This excellence in reporting has earned recognition from his peers. For example, twice Michel and The Dark Report have won national awards for best investigative reporting by the Specialty Information Publishers Association. In 2005, the award was for Michel’s coverage about how the anatomic pathology condominium laboratories (pod labs) operated by urologists and gastroenterologists came to be, who operated them, and how these owners marketed the AP condo labs to other physician groups. In 2009, Michel’s award for best investigative reporting resulted from his published interviews with Quest Diagnostics Incorporated when the company admitted that, for a period of 18 months, it had been reported inaccurate Vitamin 25(OH) D results because of problems with its laboratory-developed test methodology. The Dark Report’s story was picked up by The New York Times and was in the national news cycle for several days.
In his role as Editor-in-Chief, Michel brought unique capabilities to DIG and The Dark Report. His management training and diverse business experience—along with his skills as a concise writer and analyst—proved to be a winning combination for readers of The Dark Report. For that reason, Michel’s story has many intriguing elements.
Immediately prior to founding DIG, he had served in several executive positions for Nichols Institute based in Portland, Oregon, and San Juan Capistrano, California. This was during the time that Nichols Institute was an independent public lab company with annual revenues of about $280 million (prior to its acquisition by MetPath, Inc., now Quest Diagnostics Incorporated). He traveled extensively to many of the clinical lab business units owned by Nichols Institute in different regions of the United States and played a role in formulating effective market strategies in response to the emergence of closed-panel HMOs, capitated pricing, and full-risk managed care contracts, among other successful management initiatives.
Prior to his service at Nichols Institute, Michel served at three different Fortune 100 companies. These were Procter & Gamble, Centex Corporation, and Financial Corp. of America. Each was an opportunity to master new management techniques and apply them in different industries. Between these positions, he gained experience as an entrepreneur, having founded a real estate development firm and a general contracting company in the Southeastern United States.
Robert Michel earned a Bachelor of Arts degree in Economics at the University of California, Los Angeles, where he played rugby, a sport he participated in for another 22 years. He is a native of California and grew up in Santa Ana.
Articles by Robert Michel
Labs Can Expect COVID-19 Test Audits, Investigations
From the Volume XXIX, No. 7 – May 16, 2022 Issue
CEO SUMMARY: Billions of federal …
California Cancels COVID-19 Test Contract with PerkinElmer
From the Volume XXIX, No. 7 – May 16, 2022 Issue
CALIFORNIA HAS SHED MORE LIGHT ON THE DECISION to terminate PerkinElmer’s valuable contract to run the Valencia Branch Laboratory (VBL). The lab has been embroiled in controversy for much of its existence. The state noted that SARS-CoV-2…
IVD Firms Grow During 2022, but COVID-19 Revenue Dropped
From the Volume XXIX, No. 7 – May 16, 2022 Issue
MOST MAJOR IN VITRO DIAGNOSTICS (IVD) MANUFACTURERS started strong in 2022 as their base businesses regained steam and made up for the significant falloff in COVID-19 diagnostic test revenue. During first quarter 2022 earnings calls with invest…
May 16, 2022 Intelligence: Late-Breaking Lab News
From the Volume XXIX, No. 7 – May 16, 2022 Issue
Chalk up another lab outreach deal for Labcorp. The Burlington, N.C.-based company has agreed to acquire certain assets of AtlantiCare’s clinical laboratory outreach business. The deal was announced on May 9, with no financial terms disclosed. The outreach business of AtlantiCare, bas…
Lab Staffing Shortages Reaching Dire Levels
From the Volume XXIX, No. 6 – April 25, 2022 Issue
This is an excerpt of a 1,423-word article in the April 4, 2022 issue of THE DARK REPORT. The full article is available to members of The Dark Intelligence Group. CEO SUMMARY: Just weeks ago, CAP Today characterized the current lab staffing shortage as going “from simmer t…
‘Lab Workforce Crisis Takes Top Spot’–CAP Today
From the Volume XXIX, No. 6 – April 25, 2022 Issue
CEO SUMMARY: Just weeks ago, CAP Today characterized the current crisis in staffing clinical laboratories as going “from simmer to rolling boil.” Demand for medical technologists and other certified laboratory scientists far exceeds the supply. Consequently, many labs now…
U.K.-based CliniSys Acquires Nashville-based ApolloLIMS
From the Volume XXIX, No. 6 – April 25, 2022 Issue
CONSOLIDATION IN THE CLINICAL LABORATORY INFORMATICS INDUSTRY took another step forward with the announcement that CliniSys (the parent of Sunquest Information Systems) was acquiring Nashville-based ApolloLIMS. This move may also further muddy the line between classic laborato…
Problems at Theranos Described in Balwani Trial
From the Volume XXIX, No. 6 – April 25, 2022 Issue
CEO SUMMARY: Former Theranos President and COO Ramesh Balwani is now being tried in federal court in San Jose, Calif. As with the earlier trial of Elizabeth Holmes, questions will arise about whether executives or clinical lab directors bear ultimate responsibility for lab test resu…
DOJ: EKRA Governs Lab Sales and Marketing Commissions
From the Volume XXIX, No. 6 – April 25, 2022 Issue
BY FILING A MOTION IN A U.S. DISTRICT COURT RECENTLY, officials from the federal Department of Justice (DOJ) took steps to oppose an earlier ruling by a federal judge in Hawaii dealing with the way the Eliminating Kickbacks in Recovery Act of 2018 (EKRA) governs how percentage-based commission…
Anticipating Change in COVID-19 Test Volume
From the Volume XXIX, No. 6 – April 25, 2022 Issue
CEO SUMMARY: New and more easily transmitted variants of SARS-CoV-2 are causing surges…
CURRENT ISSUE

Volume XXXII, No. 10 – July 14, 2025
This issue is strong on different flavors of enforcement that clinical laboratories, whether they want to or not, will need to contend with. Lab stakeholders provide insights that medical labs need to brace for more action to counter pending test reimbursement rate cuts under PAMA. Also, this issue provides the legal and regulatory landscape for clinical labs’ use of AI and how it evolves with the technology. AI is creating legal uncertainty for clinical labs, especially around data privacy and FDA oversight of AI tools in diagnostics.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized